 |
|
|
|
April 2001 Cover
|
|
Pfizer revealed that it has halted late-stage human trials of capravirine, a potential blockbuster AIDS medicine, after a year-long trial of the medication in dogs showed that very high doses of the drug caused inflamed blood vessels, or vasculitis. Pfizer said that the
Food and Drug Administration is helping the company to create further safety tests in animals.
The firm noted that none of the 650 human patients in six clinical trials of capravirine had any indications of vasculitis. Most patients will end their capravirine regimen in favor of other treatments, but those who are doing well with the drug and have failed
other therapies will remain on the drug; both groups will be monitored by Pfizer scientists.
Editor's Note: from The Wall Street Journal
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
